Radiolabelled antibody cytotoxic therapy of infectious or autoimmune disease

• US 5,609,846 A
• Filed: 03/27/1995
• Issued: 03/11/1997
• Est. Priority Date: 03/29/1988
• Status: Expired due to Term

• Current Assignee: Immunomedics, Inc. (Gilead Sciences Inc.)
• Original Assignee: Immunomedics, Inc. (Gilead Sciences Inc.)
• Inventors: Goldenberg, Milton D.
• Primary Examiner(s): Kight, John
• Assistant Examiner(s): KELLEY, LARA CHAPMAN
• Application Number:
  US08/412,225
• Time in Patent Office: 715 Days
• Field of Search: 424/1.1, 424/1.41, 424/1.53, 424/1.65, 424/1.69, 424/144.1, 424/85.1, 424/85.2, 424/85.4
• US Class Current: 424/1.41
• CPC Class Codes: A61K 2121/00 Preparations for use in therapy
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 39/44 Antibodies bound to carriers
• CPC Class Codes: A61K 47/6813 the drug being a peptidic cytokine, e.g. an interleukin or interferon

Abstract

Anticancer, antimicrobial and autoimmune disease, and anti-organ rejection therapy using cytotoxic agents is improved using cytokines to prevent, mitigate or reverse adverse radiation-induced or drug-induced toxicity, especially to hematopoietic cells. Cytotoxic agents can include radioisotopes, drugs, toxins and even unconjugated cytotoxic antibodies. A preferred cytokine is IL-1. Higher doses of cytotoxic agents can be administered and tolerated by the patient and dose-limiting marrow toxicity can be prevented, palliated or reversed using adjunct cytokine therapy.

Claims

1. In a method of therapy of an infectious or autoimmune disease, wherein a human patient suffering from an infectious or autoimmune disease susceptible to treatment with a cytotoxic agent is treated with a therapeutic amount of a cytotoxic agent which also produces hematopoietic or myeloid toxicity,

the improvement which comprises administering to said patient an amount effective for substantially preventing, mitigating or reversing such hematopoietic or myeloid toxicity, of interleukin-1 (IL-1) alone or in combination with one or more additional differentiation/maturation-inducing cytokines other than interleukin-2, prior to, simultaneously with or subsequent to exposure to said cytotoxic agent;

wherein said cytotoxic agent is a radioisotope, drug or toxin conjugated to an antibody or antibody fragment which specifically binds to an antigen which is produced by or associated with an infectious agent or a non-cancerous lymphocyte, provided that said cytotoxic agent is not tumor necrosis factor (TNF).

2. The method of claim 1, wherein said antibody or antibody fragment specifically binds to an antigen which is produced by or associated with an infectious microorganism.

3. The method of claim 2, wherein interleukin-1 (IL-1) is administered alone.

4. The method of claim 3, wherein said interleukin-1 (IL-1) is administered by intravenous or intraarterial continuous infusion.

5. The method of claim 3, wherein said interleukin-1 (IL-1) is administered from two days prior to seven days after exposure to said cytotoxic agent.

6. The method of claim 2, wherein said one or more additional cytokines is one or more of interleukin-3 (IL-3), granulocyte macrophage-colony stimulating factor (GM-CSF), granulocyte-colony stimulating factor (G-CSF), macrophage-colony stimulating factor (M-CSF), or platelet growth factor.

7. The method of claim 6, wherein said one or more cytokines is interleukin-3 (IL-3).

8. The method of claim 2, wherein said radioisotope, drug or toxin conjugate is administered by an intravenous or intraarterial route.

9. The method of claim 2, wherein said radioisotope, drug or toxin conjugate is administered by an intrathecal, intracavitary, intramuscular, subcutaneous or oral route.

10. The method of claim 2, wherein said one or more additional cytokinesis one or more of interleukin-3 (IL-3), macrophage-colony stimulating factor (M-CSF) or platelet growth factor.

11. The method of claim 1, wherein a radioisotope conjugate is administered.

12. The method of claim 11, wherein said radioisotope is generated in situ by neutron irradiation of Boron-10 atoms.

13. The method of claim 11, wherein said radioisotope is a beta-emitter.

14. The method of claim 11, wherein said radioisotope is as alpha-emitter.

15. The method of claim 11, wherein interleukin-1 (IL-1) is administered alone.

16. The method of claim 11, wherein said one or more additional cytokines is one or more of interleukin-3 (L-3), granulocyte macrophage-colony stimulating factor (GM-CSF), granulocyte-colony stimulating factor (G-CSF), macrophage-colony stimulating factor (M-CSF), or platelet growth factor.

17. The method of claim 16, wherein said one or more cytokines is interleukin-3 (IL-3).

18. The method of claim 11, wherein said one or more additional cytokines is one or more of interleukin-3 (IL-3), macrophage-colony stimulating factor (M-CSF) or platelet growth factor.

19. The method of claim 1, wherein a drug conjugate is administered.

20. The method of claim 19 wherein said drug is an antimicrobial drug.

21. The method of claim 20 wherein said antimicrobial drug is an antiviral drug.

22. The method of claim 1, wherein a toxin conjugate is administered.

23. The method of claim 22, wherein said toxin is an antimicrobial toxin.

24. The method of claim 1, wherein said interleukin-1 (IL-1) is administered prior to or simultaneously with administration of said radioisotope, drug or toxin conjugate.

25. The method of claim 1, wherein said interleukin-1 (IL-1) is administered subsequent to administration of said radioisotope, drug or toxin conjugate.

26. The method of claim 25, wherein said interleukin-1 (IL-1) is administered at least 3 days after administration of said radioisotope, drug or toxin conjugate.

27. The method of claim 1, wherein said radioisotope, drug or toxin conjugate is administered by an intravenous or intraarterial route.

28. The method of claim 1, wherein said radioisotope, drug or toxin conjugate is administered by an intrathecal, intracavitary, intramuscular, subcutaneous or oral route.

29. The method of claim 1, wherein interleukin-1 (IL-1) is administered alone.

30. The method of claim 1, wherein said one or more additional cytokines is one or more of interleukin-3 (IL-3), granulocyte macrophage-colony stimulating factor (GM-CSF), granulocyte-colony stimulating factor (G-CSF), macrophage-colony stimulating factor (M-CSF), or platelet growth factor.

31. The method of claim 30, wherein said one or more cytokines is interleukin-3 (IL-3).

32. The method of claim 30, wherein said one or more additional cytokines is one or more of interleukin-3 (IL-3), macrophage-colony stimulating factor (M-CSF) or platelet growth factor.

33. The method of claim 1, further comprising administering a second antibody or antibody fragment which specifically binds to said cytotoxic agent at a time from 3 to 72 hours after exposure to said cytotoxic agent and in an amount sufficient to enhance clearance of said cytotoxic agent from the circulation.

34. The method of claim 1, wherein said interleukin-1 (IL-1) and said one or more additional cytokines is administered by intravenous or intraarterial continuous infusion.